Supporting Online Material for
|
|
- Bethany Armstrong
- 5 years ago
- Views:
Transcription
1 Supporting Online Material for Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James C. Yang, Richard M. Sherry, Richard E. Royal, Suzanne L. Topalian, Udai S. Kammula, Nicholas P. Restifo, Zhili Zheng, Azam Nahvi, Christiaan R. de Vries, Linda J. Rogers-Freezer, Sharon A. Mavroukakis, Steven A. Rosenberg* *To whom correspondence should be addressed. This PDF file includes: Materials and Methods Tables S1 to S5 References Published 31 August 2006 on Science Express DOI: /science
2 1 Supplemental On-line Material Methods Patient Peripheral Blood Mononuclear Cells (PBMC), and cell lines. All of the Peripheral Blood Lymphocytes (PBL) used in this study were cryopreserved PBMC obtained by leukapheresis of metastatic melanoma patients treated at the Surgery Branch, National Cancer Institute, NIH, Bethesda, MD. T2 is a lymphoblastoid cell line deficient in TAP function, whose HLA class I proteins can be easily loaded with exogenous peptides(1). Melanoma lines 938mel, 888mel, 624mel, and 526mel were generated at the Surgery Branch from resected tumor lesions. Other cell lines used were non-small cell lung cancer line H2087 (ATCC/CRL-5922), breast cancer line MDA 453 (ATCC/HTB-131), the human lymphoid cell line Sup T1 (ATCC CRL-1942), and PG13 gibbon ape leukemia virus packaging cell line (ATCC CRL 10,686). All the cell lines described above were maintained in R10 (RPMI1640, Invitrogen Corp, Grand Isle, NY) supplemented with 10% FCS (Biofluids, Inc., Gaithersburg, MD). Culture medium (CM) for established human T lymphocyte lines was RPMI1640 with 0.05mM mercaptoethanol, 300 IU/ml interleukin-2 (IL-2) (Chiron Corp. Emerville, CA) plus 10% human AB serum (Valley Biomedical Winchester, VA). Patient Treatment This human gene therapy protocol was reviewed and approved by the National Institutes of Health institutional biosafety committee, National Cancer Institute institutional review board,
3 2 recombinant DNA advisory committee of the Office of Biotechnology Activities, Office of the Director, National Institutes of Health, and the Center for Biologics Evaluation and Research of the Food and Drug Administration (all, Bethesda, MD). Patients eligible for treatment on this protocol were older than 18 years, HLA-A0201+, HIV infection, hepatitis B and C negative with a life expectancy greater than 3 months with good performance status. All patients signed institutional review board-approved consents and had their pathology confirmed by pathologists at the Clinical Center, National Institutes of Health in Bethesda, MD. All patients had measurable disease on computed tomography scan, magnetic resonance imaging or by physical exam. Tumor response was determined by RECIST criteria(2). Patients were required to have progressed after prior interleukin-2 therapy before enrollment and did not have tumor infiltrating lymphocyte cultures available for treatment. PBMC were isolated by leukapheresis, separated by centrifugation on a ficoll-hypaque cushion, washed in HBSS, then resuspended at a concentration of 1 X 10 6 /ml in T-cell culture medium AIM-V (Invitrogen Corp, Grand Isle, NY) with 300IU/ml IL-2, 100U/ml penicillin, 100µg/ml streptomycin, 1.25µg/ml amphotericin, 10µg/ml ciprofoloxicin, and 5% human AB serum supplemented with 50ng/ml OKT3. After 2 days of culture, cells were collected, resuspended in fresh T cell culture medium without OKT3. A retroviral vector (MSGV1AIB) was constructed(3) and optimized to express the MART-1 TCR alpha and beta chains using an Murine Stem Cell Virus (MSCV) long terminal repeat (LTR) (known to be relatively resistant to in vivo silencing), incorporating the splicing and optimized start codon of the MFG-design of vectors, and the use of a highly efficient internal ribosome entry site (IRES) derived from the human polio virus(4). After selection of high-titer producer cell
4 3 clones a clinical grade retroviral vector supernatant was produced and used in a solid-phase transduction protocol that resulted in highly efficient gene transfer without the use of any selection method. The transduction of up to 5 X 10 8 cells was performed by overnight culture on Retronectin (CH-296, GMP grade Retronectin purchased from Takara Bio. Inc, Japan) coated, MSGV1AIB vector-preloaded six well tissue culture plates, using 6 ml vector and up to 5 X 10 6 cells per well. In cohorts 1 and 3, PBL were transferred the following day to a second set of pre-coated Retronectin/retroviral vector tissue culture plates. Patients in cohort 2, received cells with only one cycle of transduction. Two days after the last transduction, the PBL cultures were assayed for the presence of Vβ12 TCR protein by FACS analysis and for activity by cytokine release assay. An initial cohort of three patients was treated with cells following an extended culture period of 19 days at which point they had cell doubling times ranging from 8.7 to 11.9 days (Table 1, cohort 1; patients 1, 2a, 3). In an effort to administer gene-modified lymphocytes that were in their active growth phase, we modified the culture conditions to limit the ex vivo culture time to 6 to 9 days after stimulation of cells with OKT-3. This modification was based on prior animal and human data indicating that the in vivo proliferation and persistence of the transferred cells was highly correlated with their ability to mediate cancer regression(5-9). Thus patient lymphocytes were stimulated with OKT-3, transduced and administered either on days 6, 7, or 8 at which time they had doubling times of two days or less (Table 1, cohort 2; 11 patients). To generate larger numbers of actively dividing cells for ACT, we cultured transduced cells for days, exposing a portion of the culture to an OKT-3 based rapid expansion protocol(10) after 8-9 days (Table 1, cohort 3; 4 patients).
5 4 The doubling time of the cells in cohort 3 was 0.9 to 3.3 days. The mean number of cells infused in cohort 2 was 6.2 X 10 9 and in cohort 3 was 45.3 X All patients received nonmyeloablative lymphodepleting chemotherapy, consisting of 2 days of cyclophosphamide (60mg/kg) and 5 days of fludarabine (25mg/m 2 ). One to four days after the final dose of chemotherapy, patients received MSGV1AIB (anti-mart-1 TCR) transduced lymphocytes by intravenous bolus infusion over thirty minutes. Patients then received high dose intravenous IL-2 (720,000 IU/kg every eight hours to tolerance or a maximum of 12 doses), and MART-1:27-36(27L) peptide vaccine (1 mg peptide, manufactured by the National Cancer Institute through a contract with Ben Venue Laboratories) emulsified in Montanide ISA-51 (Seppic, Inc., Fairchild, NJ) by intramuscular injection on days 1, 2, 3, 4, 5, 12, and 19 after cell infusion. Electroporation of in vitro transcribed mrna. mrna encoding the GFP was prepared from pgem4z/egfp/a64 (kindly provided by Dr, Eli Gilboa, Duke University Medical Center. Durham, NC). mrna encoding TCR α and β chains of MART-1, gp100, NY-ESO-1, and p53 were prepared from PCR products made using gene specific primer pairs containing the T7 RNA polymerase promoter sequence(11). mmassage mmachine High Yield Capped RNA transcription Kit (Ambion Inc. Austin TX)was utilized to generate in vitro transcribed (IVT) RNA. The IVT RNA was purified using an RNeasy Mini Kit (Qiagen, Valencia, CA) and purified RNA was resuspended in RNase free water at 1-0.5mg/ml. For the stimulation of the T cells, human PBLs were stimulated with IL-2 (300 IU/ml) plus 50 ng/ml OKT3 for 7 days, and enriched for CD8+
6 5 cells before electroporation. The stimulated CD8+ PBLs subjected to electroporation following resuspension in OPTI-MEM (Invitrogen) medium at the final concentration of 25X10 6 /ml. Cells and cuvettes were pre-chilled by putting them on ice for >5 min. For electroporation 0.2 ml of the cells were mixed with 2 µg/1x10 6 T cells of IVT RNA and electroporated in a 2 mm cuvette (Harvard Apparatus BTX, Holliston, MA), using ECM830 Electro Square Wave Porator (Harvard Apparatus BTX, Holliston, MA) at 500V/500µs. Immediately after electroporation, the cells were transferred to fresh CM with 300 IU/ml IL- 2 and incubated at 37 C until use. FACS analysis Cell surface expression of TCRVβ12, TCRVβ8, CD3, CD4, and CD8 molecules on PBL were measured using FITC, PE or APC-conjugated antibodies according to the manufacturer s instructions. Anti-TCR Vβ8 and Vβ12 were purchased from Immunotech (Westbrook, ME) and the other antibodies were from Becton Dickinson (San Jose, CA). MART-1 specific TCR were stained with a tetrameric HLA-A2/MART-1:27-36(27L) fluorochrome conjugate (itag MHC Tetramer, Beckman Coulter, Fullerton, CA) according to the manufacturer s recommendations. Cells were stained in a FACS buffer made of PBS (BioWhitaker, Walkersville, MD) and 1% FCS. Prior to staining of peripheral blood lymphocytes, Fc receptors were blocked with normal mouse IgG (Caltag Labs, Burlingame, CA). Immunofluorescence, was measured using a FACscan or FACScaliber flow cytometer (Becton Dickinson). A combination of forward angle light scatter and propidium iodide staining was used to gate out dead cells. Approximately 1 x 10 5 events were acquired. Staining was analyzed using Cell Quest (Becton Dickson) or FlowJo (Treestar, Ashland OR)
7 6 software. The Vβ12 intermediate cells were identified based on the Vβ12 profile of the preinfusion cells using markers set to exclude both CD8 + Vβ12 high and CD8 + Vβ12 negative events. Other markers were set by comparison to fluorochrome-conjugated isotype control antibodies or HLA-A2 tetramer containing an irrelevant control peptide. Cytokine release assays PBL cultures were tested for specificity and tumor reactivity in cytokine release assays. For these assays, 1x10 5 responder cells and 1x10 5 stimulator cells (T2 or human tumor lines) were incubated for 18 to 24 h in a 0.2-ml culture volume in individual wells of 96-well plates. T2 cells were pulsed with peptide (1 µg/ml) in medium for 2 h at 37 C, followed by washing (three times) before initiation of co-cultures. Ex vivo lymphocyte activity was measured after overnight culture in T cell medium supplemented with 300 IU/ml IL-2. Cytokine secretion was measured in culture supernatants diluted as to be in the linear range of the assay using commercially available ELISA kits (IFN-γ, Endogen, Cambridge, MA) according to the manufacturer s recommendations. Analysis of gene marked cells. The persistence of the gene-marked cells was determined from patient PBMC. Genomic DNA was isolated using QIAamp DNA Blood Midi Kit (Qiagen, Valencia, CA) according to the manufacture s instruction. 100ng of each DNA was used for the Real-time quantitative PCR assay (TaqMan, Applied Biosystems Inc, Foster City, CA). Total RNA was isolated from PBL using RNeasy Mini Kit (Qiagen). 1µg of total RNA was used in the first strand of cdna synthesis reaction using ThermoScript RT-PCR System (Invitrogen,
8 7 Carlsbad, CA) using random hexamers and diluted 10-fold with RNA-free water after the reaction. One tenth of the diluted reaction mix was used later for the real-time quantitative PCR (TaqMan). All PCR reactions were performed using an ABI 7500 Fast Real-time PCR System instrument(applied Biosystems Inc,). The TaqMan gene specific assay was designed by ABI Assays-by-Design SM software (Applied Biosytems Inc.,) using as target, the sequence between TCR α and IRES genes. The assay primers/probe were: 5 - GCCGGGTTTAATCTGCTCATG-3 (AIBAI-forward primer); 5 -GCCGGGTTTAATCTGCTCATG -3 (AIBAI-reverse primer), and 5 -FAM-TCCAGCTGAACTAGAACTA-3 (AIBAI- FAM labeled probe). The reference standard curve was established using the genomic DNA from a MSGV1AIB transduced SupT1 cell clone by mixing known ratios of genomic DNA into untransduced SupT1 cell DNA. TaqMan β-actin control reagents kit (Applied Biosytems Inc.,) was used to normalize reactions to input RNA/DNA amounts.
9 8 Supplemental References 1. R. D. Salter, D. N. Howell, P. Cresswell, Immunogenetics 21, 235 (1985). 2. P. Therasse et al., J Natl Cancer Inst 92, 205 (Feb 2, 2000). 3. M. S. Hughes et al., Hum Gene Ther 16, 457 (Apr, 2005). 4. R. A. Morgan et al., Nucleic Acids Res 20, 1293 (Mar 25, 1992). 5. J. Zhou et al., J Immunol 175, 7046 (Nov 15, 2005). 6. J. Zhou, M. E. Dudley, S. A. Rosenberg, P. F. Robbins, J Immunother 28, 53 (Jan- Feb, 2005). 7. P. F. Robbins et al., J Immunol 173, 7125 (Dec 15, 2004). 8. J. Huang et al., J Immunother 28, 258 (May-Jun, 2005). 9. L. Gattinoni et al., J Exp Med 202, 907 (Oct 3, 2005). 10. S. R. Riddell, P. D. Greenberg, J Immunol Methods 128, 189 (Apr 17, 1990). 11. Y. Zhao et al., Mol Ther 13, 151 (Jan, 2006).
10 9 Supplemental Table1. RNA electroporation of tumor antigen specific TCR. Effector TCR RNA Tumor GFP MART-1 gp100 NY-ESO-1 p53 938mel mel H >1654 MDA 435S-A MDA 435S CD8+ PBLs were electroporated with IVT GFP RNA or tumor antigen specific TCRs (MART-1, gp100, NY-ESO-1, p53). Two hours post electroporation, the cells were cocultured with tumor cell lines and after overnight co-culture, the supernatants were collected and subjected to ELISA detection of interferon-γ secretion (in pg/ml). The known phenotypes of these tumor cell line were; melanoma 938mel (HLA-A2-/MART- 1+/gp100+), melanoma 526mel (HLA-A2+/MART-1+/gp100+/p53+), non-small cell lung cancer H2087 (HLA-A2+/NY-ESO-1-/p53+), breast cancer MDA 453S-A2 (HLA- A2+/NY-ESO-1+/p53-), and breast cancer MDA 453S (HLA-A2-/NY-ESO-1+/p53-). Values demonstrating specific release of cytokine are in bold.
11 10 Supplemental Table 2, Gene transfer efficiency at time of infusion. Patient Number 1 2a b Ave Vβ12 (%CD4) Tetramer (%CD4) Vβ12 (%CD8) Tetramer (%CD8) n/d n/d Samples were taken from transduced T lymphocytes cultures at or near time of infusion. FACS analysis for CD4, CD8, Vβ12, and MART-1 Tetramer (M27L) was as described in methods. n/d, not determined.; Ave, average value.
12 11 Supplemental Table 3, Q-RT PCR Analysis Patient Number Infusion Post Infusion Amount of TCR vector-derived RNA normalized to cellular actin mrna. Using RNA derived from a stable transduced human T cell line (Sup T1) as reference; total RNA from infused T cells or patient PBMC post-infusion were subjected to Q-RT PCR and then normalized to the amount of actin mrna (values are vector/1 x 10 6 actin). Samples were 2-5 weeks post-infusion, with exception of patients 8, 9, and 11, which were 2 months, 3 months, and 2 weeks respectively.
13 12 Supplemental Table 4, Elispot Analysis Patient Number 1 2a b Infusion Pre treatment Post infusion Number of interferon-γ positive Eispots/100,000 cells. Post-infusion values derived from PBL taken at one to four weeks post-infusion and rested overnight in medium (without cytokine) prior to assay.
14 13 Supplemental Table 5. Antigen reactivity of ex vivo cultured PBL. Patient 4: Melanoma Cell Line A2- A2+ Peptide pulsed T2 cells None gp100 MART µm 10 µm 1.0 µm None A1,24 A1,24 A2,3 A2,3 Controls None AK JKF >16910 > JR6C Patient 4 Pretreatment Day >1255 > Day Day µm Anti-melanoma properties of genetically engineered lymphocytes determined for patient 4 PBL following overnight culture in IL-2 (300 IU/ml). The production of interferon-γ (pg/ml) following co-culture with peptide pulsed T2 cells (peptide reactivity) and anti-melanoma activity (tumor reactivity) for HLA-A2 + lines (526, 624) and HLA-A2- lines (888, 938). Controls included; non-peptide reactive TIL AK , MART-1 reactive TIL JKF6, and gp100 reactive TIL JR6C12. JR6C12 recognition of 1.0µM MART-1 peptide was not reproducible in repeated assays. Values demonstrating specific release of cytokine are in bold.
15 14 Patient 14: Melanoma Cell Line A2- A2+ Peptide pulsed T2 cells None gp100 MART None A1,24 A1,24 A2,3 A2,3 µm 10 µm 1.0 µm 0.1 µm Controls None AK >2168 >2168 >182 JKF6 8 JR6C > Patient 14 Pretreatment Day Day Day Day Day Day Anti-melanoma properties of genetically engineered lymphocytes determined for patient 14 PBL following overnight culture in IL-2 (300 IU/ml). The production of interferon-γ (pg/ml) following co-culture with peptide pulsed T2 cells (peptide reactivity) and anti-melanoma activity (tumor reactivity) for HLA-A2 + lines (526, 624) and HLA-A2- lines (888, 938). Controls included; non-peptide reactive TIL AK , MART-1 reactive TIL JKF6, and gp100 reactive TIL JR6C12. Values demonstrating specific release of cytokine are in bold.
NIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.
NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationPBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human
Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation
More informationEx vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*
Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University
More informationSupporting Information
Supporting Information Chapuis et al. 10.1073/pnas.1113748109 SI Methods Selection of Patients, Targets, Isolation, and Expansion of Melanoma- Specific CTL Clones. Patients were HLA-typed, and their tumors
More informationDetailed step-by-step operating procedures for NK cell and CTL degranulation assays
Supplemental methods Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Materials PBMC isolated from patients, relatives and healthy donors as control K562 cells (ATCC,
More informationSupplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in
Supplementary Data 1. Alanine substitutions and position variants of APNCYGNIPL. Applied in Supplementary Fig. 2 Substitution Sequence Position variant Sequence original APNCYGNIPL original APNCYGNIPL
More informationCommercially available HLA Class II tetramers (Beckman Coulter) conjugated to
Class II tetramer staining Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to PE were combined with dominant HIV epitopes (DRB1*0101-DRFYKTLRAEQASQEV, DRB1*0301- PEKEVLVWKFDSRLAFHH,
More informationHigh-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation Yangbing Zhao, Zhili Zheng, Cyrille J. Cohen, Luca Gattinoni, Douglas C. Palmer, Nicholas P. Restifo, Steven
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationSupplementary Data Table of Contents:
Supplementary Data Table of Contents: - Supplementary Methods - Supplementary Figures S1(A-B) - Supplementary Figures S2 (A-B) - Supplementary Figures S3 - Supplementary Figures S4(A-B) - Supplementary
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Chandran SS, Somerville RPT, Yang JC, et al.
More informationSupplementary Materials for
immunology.sciencemag.org/cgi/content/full/2/16/eaan6049/dc1 Supplementary Materials for Enzymatic synthesis of core 2 O-glycans governs the tissue-trafficking potential of memory CD8 + T cells Jossef
More informationSUPPLEMENTARY INFORMATION. Involvement of IL-21 in the epidermal hyperplasia of psoriasis
SUPPLEMENTARY INFORMATION Involvement of IL-21 in the epidermal hyperplasia of psoriasis Roberta Caruso 1, Elisabetta Botti 2, Massimiliano Sarra 1, Maria Esposito 2, Carmine Stolfi 1, Laura Diluvio 2,
More informationRNA extraction, RT-PCR and real-time PCR. Total RNA were extracted using
Supplementary Information Materials and Methods RNA extraction, RT-PCR and real-time PCR. Total RNA were extracted using Trizol reagent (Invitrogen,Carlsbad, CA) according to the manufacturer's instructions.
More informationSupplementary Figure 1. Example of gating strategy
Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte
More informationArtificial Antigen Presenting Cells as a Standardized Platform for Tumor Infiltrating Lymphocyte (TIL) expansion
Artificial Antigen Presenting Cells as a Standardized Platform for Tumor Infiltrating Lymphocyte (TIL) expansion Concurrent Session 404: T cell Manufacturing and Potency 27 th Annual Meeting of the Society
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationSupplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR
Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationSupplemental Information. T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism
Immunity, Volume 33 Supplemental Information T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism Franziska Petermann, Veit Rothhammer, Malte
More informationRapid antigen-specific T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154+CD4+ T cell Rapid antigen-specific T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central role
More informationIslet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot
Islet viability assay and Glucose Stimulated Insulin Secretion assay Islet cell viability was determined by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay using CellTiter
More informationNIH Public Access Author Manuscript Cancer Res. Author manuscript; available in PMC 2007 December 3.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Res. 2007 March 15; 67(6): 2425 2429. Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationThe toll-like receptor 4 ligands Mrp8 and Mrp14 play a critical role in the development of autoreactive CD8 + T cells
1 SUPPLEMENTARY INFORMATION The toll-like receptor 4 ligands Mrp8 and Mrp14 play a critical role in the development of autoreactive CD8 + T cells Karin Loser 1,2,6, Thomas Vogl 2,3, Maik Voskort 1, Aloys
More informationAdoptive T Cell Therapy TILs & TCRs & CARs
Adoptive T Cell Therapy TILs & TCRs & CARs Inge Marie Svane CCIT DENMARK Professor, MD Center for Cancer Immune Therapy Department of Oncology, Herlev Hospital Copenhagen University Denmark Therapeutic
More informationGladstone Institutes, University of California (UCSF), San Francisco, USA
Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24 Gag Marianne Gesner, Mekhala Maiti, Robert Grant and Marielle Cavrois * Gladstone Institutes, University of
More informationDirect ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE)
Direct ex vivo characterization of human antigen-specific CD154 + CD4 + T cells Rapid antigen-reactive T cell enrichment (Rapid ARTE) Introduction Workflow Antigen (ag)-specific T cells play a central
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationNIH Public Access Author Manuscript J Immunother. Author manuscript; available in PMC 2008 February 10.
NIH Public Access Author Manuscript Published in final edited form as: J Immunother. 2008 January ; 31(1): 1 6. T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model John D. Abad
More informationBioassays for Quality Control of Cell & Gene Therapy Products
Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen
More informationRecombinant Protein Expression Retroviral system
Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential
More informationImmunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
1 of 9 12/03/2015 17:02 Nat Med. Author manuscript; available in PMC 2007 Nov 6. Published in final edited form as: Nat Med. 1998 Mar; 4(3): 321 327. PMCID: PMC2064864 NIHMSID: NIHMS30924 Immunologic and
More informationAdoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion
This information is current as of October 4, 2017. References Subscription Permissions Email Alerts Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma
More informationSupplementary Data. Treg phenotype
Supplementary Data Additional Experiment An additional experiment was performed using cryopreserved peripheral blood mononuclear cells (PBMC) derived from five renal cell carcinoma (RCC) patients [see
More informationSupporting Online Material for
www.sciencemag.org/cgi/content/full/1175194/dc1 Supporting Online Material for A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection John S. Yi, Ming Du, Allan J. Zajac* *To whom
More informationSupplementary Information
Supplementary Information Supplementary Figure 1. CD4 + T cell activation and lack of apoptosis after crosslinking with anti-cd3 + anti-cd28 + anti-cd160. (a) Flow cytometry of anti-cd160 (5D.10A11) binding
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationCell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice
Supplementary Methods: Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice and gently meshed in DMEM containing 10% FBS to prepare for single cell suspensions. CD4 + CD25
More informationTodd D. Prickett Ph.D. Surgery Branch/NCI/NIH. Dr. Steven A. Rosenberg Branch Chief Dr. Paul F. Robbins Surgery Branch/NCI/NIH
Durable Complete Response in a Patient with Metastatic Melanoma Following Adoptive Transfer of Autologous T cells Recognizing 1 Mutated Tumor Antigens Todd D. Prickett Ph.D. Surgery Branch/NCI/NIH Dr.
More informationEffective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features
Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al. Clin Cancer Res
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationSupplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12
1 Supplementary Data Figure legends Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12 serum levels measured by multiplex ELISA (Luminex) in FL patients before
More informationSupplemental Methods In vitro T cell assays Inhibition of perforin- and FasL-mediated cytotoxicity Flow Cytometry
Supplemental Methods In vitro T cell assays Cell lines Jurkat (ATCC #TIB-152), CCRF-CEM (ATCC #CCL-119), MOLT-4 (ATCC #CRL- 1582), Hut 78 (ATCC #TIB-161), SupT1 (ATCC #CRL-1942), Raji (ATCC #CCL-86) and
More information<10. IL-1β IL-6 TNF + _ TGF-β + IL-23
3 ns 25 ns 2 IL-17 (pg/ml) 15 1 ns ns 5 IL-1β IL-6 TNF
More informationPair-fed % inkt cells 0.5. EtOH 0.0
MATERIALS AND METHODS Histopathological analysis Liver tissue was collected 9 h post-gavage, and the tissue samples were fixed in 1% formalin and paraffin-embedded following a standard procedure. The embedded
More informationSupplementary data Supplementary Figure 1 Supplementary Figure 2
Supplementary data Supplementary Figure 1 SPHK1 sirna increases RANKL-induced osteoclastogenesis in RAW264.7 cell culture. (A) RAW264.7 cells were transfected with oligocassettes containing SPHK1 sirna
More informationL-selectin Is Essential for Delivery of Activated CD8 + T Cells to Virus-Infected Organs for Protective Immunity
Cell Reports Supplemental Information L-selectin Is Essential for Delivery of Activated CD8 + T Cells to Virus-Infected Organs for Protective Immunity Rebar N. Mohammed, H. Angharad Watson, Miriam Vigar,
More informationCancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.
Cancer Immunotherapy CANCER BIOLOGY April 15, 2009 Can the immune system be harnessed to fight cancer? Can the immune system see cancer? What is the best way to turn on the immune system to fight cancer?
More informationOnline Data Supplement. Anti-aging Gene Klotho Enhances Glucose-induced Insulin Secretion by Upregulating Plasma Membrane Retention of TRPV2
Online Data Supplement Anti-aging Gene Klotho Enhances Glucose-induced Insulin Secretion by Upregulating Plasma Membrane Retention of TRPV2 Yi Lin and Zhongjie Sun Department of physiology, college of
More informationNK cell flow cytometric assay In vivo DC viability and migration assay
NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with
More informationFigure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.
Figure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.129-Gt(ROSA)26Sor tm1(cre/ert2)tyj /J mice. To induce deletion of the Pten locus,
More informationSupplementary Figure 1. Ex vivo IFNγ production by Tregs. Nature Medicine doi: /nm % CD127. Empty SSC 98.79% CD25 CD45RA.
SSC CD25 1.8% CD127 Empty 98.79% FSC CD45RA CD45RA Foxp3 %IFNγ + cells 4 3 2 1 + IL-12 P =.3 IFNγ p=.9 %IL-4+ cells 3 2 1 IL-4 P =.4 c %IL-1 + cells IFNγ 4 3 2 1 Control Foxp3 IL-1 P =.41.64 4.76 MS 2.96
More informationJunko Matsuzaki 1, Takemasa Tsuji 1*, Thinle Chodon 1, Courtney Ryan 2, Richard C. Koya 1 and Kunle Odunsi 1,3*
Matsuzaki et al. Journal for ImmunoTherapy of Cancer (2019) 7:7 https://doi.org/10.1186/s40425-018-0467-y RESEARCH ARTICLE Open Access A rare population of tumor antigen-specific CD4 + CD8 + double-positive
More informationCytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
More informationSUPPLEMENTARY METHODS
SUPPLEMENTARY METHODS Histological analysis. Colonic tissues were collected from 5 parts of the middle colon on day 7 after the start of DSS treatment, and then were cut into segments, fixed with 4% paraformaldehyde,
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationHIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)
HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual) BACKGROUND Human Immunodeficiency Virus ( HIV ) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to
More informationPrimary Adult Naïve CD4+ CD45RA+ Cells. Prepared by: David Randolph at University of Alabama, Birmingham
Primary Adult Naïve CD4+ CD45RA+ Cells Prepared by: David Randolph (drdrdr@uab.edu) at University of Alabama, Birmingham Goal: To obtain large numbers of highly pure primary CD4+ CD45RO- CD25- cells from
More informationHuman and mouse T cell regulation mediated by soluble CD52 interaction with Siglec-10. Esther Bandala-Sanchez, Yuxia Zhang, Simone Reinwald,
Human and mouse T cell regulation mediated by soluble CD52 interaction with Siglec-1 Esther Bandala-Sanchez, Yuxia Zhang, Simone Reinwald, James A. Dromey, Bo Han Lee, Junyan Qian, Ralph M Böhmer and Leonard
More informationMechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI
Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI Problems Virus escape from immune recognition Antagonism of T cell responses Peptide-MHC-TCR interaction T cell antagonism Variants of
More informationSUPPLEMENTARY INFORMATION. Divergent TLR7/9 signaling and type I interferon production distinguish
SUPPLEMENTARY INFOATION Divergent TLR7/9 signaling and type I interferon production distinguish pathogenic and non-pathogenic AIDS-virus infections Judith N. Mandl, Ashley P. Barry, Thomas H. Vanderford,
More informationSupplementary Figures
Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.
More informationSupporting Information
Supporting Information van der Windt et al. 10.1073/pnas.1221740110 SI Materials and Methods Mice and Reagents. C57BL/6 and major histocompatibility complex class I-restricted OVA-specific T-cell receptor
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationMAIT cell function is modulated by PD-1 signaling in patients with active
MAIT cell function is modulated by PD-1 signaling in patients with active tuberculosis Jing Jiang, M.D., Xinjing Wang, M.D., Hongjuan An, M.Sc., Bingfen Yang, Ph.D., Zhihong Cao, M.Sc., Yanhua Liu, Ph.D.,
More informationAdoptive cell therapy using genetically modified antigen-presenting cells
Adoptive cell therapy using genetically modified antigen-presenting cells Naoto Hirano Ontario Cancer Institute Princess Margaret Cancer Centre University of Toronto UofT-USP Oncology Conference November
More informationChallenges in Development and Validation of an Intracellular Cytokine Staining assay
Challenges in Development and Validation of an Intracellular Cytokine Staining assay Jenny Hendriks, Crucell Hatching @ EBF, Brussels, June 202 www.crucell.com Vaccines vs Protein therapeutics Protein
More informationCD14 + S100A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer
CD14 + S1A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer Po-Hao, Feng M.D., Kang-Yun, Lee, M.D. Ph.D., Ya-Ling Chang, Yao-Fei Chan, Lu- Wei, Kuo,Ting-Yu
More informationHuman Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set
Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set Catalog Number : SEK11695 To achieve the best assay results, this manual must be read carefully before using this product
More informationSupporting Information
Supporting Information Palmisano et al. 10.1073/pnas.1202174109 Fig. S1. Expression of different transgenes, driven by either viral or human promoters, is up-regulated by amino acid starvation. (A) Quantification
More informationp47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO
Supplementary Information p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO Yuri Shibata, Masaaki Oyama, Hiroko Kozuka-Hata, Xiao Han, Yuetsu Tanaka,
More informationSupplemental Figure 1
Supplemental Figure 1 1a 1c PD-1 MFI fold change 6 5 4 3 2 1 IL-1α IL-2 IL-4 IL-6 IL-1 IL-12 IL-13 IL-15 IL-17 IL-18 IL-21 IL-23 IFN-α Mut Human PD-1 promoter SBE-D 5 -GTCTG- -1.2kb SBE-P -CAGAC- -1.kb
More informationFigure S1 Time-dependent down-modulation of HER3 by EZN No Treatment. EZN-3920, 2 μm. Time, h
Figure S1 Time-dependent down-modulation of HER3 by EZN-392 HE ER3 mrna A, %Contr rol 12 No Treatment EZN-392, 2 μm 1 8 6 4 2 2 8 24 Time, h Figure S2. Specific target down-modulation by HER3 (EZN-392)
More informationYork criteria, 6 RA patients and 10 age- and gender-matched healthy controls (HCs).
MATERIALS AND METHODS Study population Blood samples were obtained from 15 patients with AS fulfilling the modified New York criteria, 6 RA patients and 10 age- and gender-matched healthy controls (HCs).
More informationHEK293FT cells were transiently transfected with reporters, N3-ICD construct and
Supplementary Information Luciferase reporter assay HEK293FT cells were transiently transfected with reporters, N3-ICD construct and increased amounts of wild type or kinase inactive EGFR. Transfections
More informationSupplementary Table 1. Functional avidities of survivin-specific T-cell clones against LML-peptide
Supplementary Table 1. Functional avidities of survivin-specific T-cell clones against LML-peptide pulsed T2 cells. clone avidity by 4-hour 51 Cr-release assay 50% lysis at E:T 10:1 [LML peptide, M] #24
More informationIn vitro human regulatory T cell expansion
- 1 - Human CD4 + CD25 + regulatory T cell isolation, Workflow in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation of T
More informationSupporting Information
Supporting Information Desnues et al. 10.1073/pnas.1314121111 SI Materials and Methods Mice. Toll-like receptor (TLR)8 / and TLR9 / mice were generated as described previously (1, 2). TLR9 / mice were
More informationT H 1, T H 2 and T H 17 polarization of naïve CD4 + mouse T cells
A complete workflow for cell preparation, isolation, polarization and analysis T H 1, T H 2 and T H 17 polarization of naïve CD4 + mouse T cells Introduction Workflow CD4 + T helper (T H) cells play a
More informationLAB 1, Immunology. Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007
LAB 1, Immunology Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007 QUANTIFICATION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY AND DETECTION OF FAS/TRAILR INDUCED APOPTOSIS RESPONSIBLE:
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationSupplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs
Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs (idcs) and mature DCs (mdcs). A myeloma cell line expressing
More informationIFN-γ Secretion Assay Detection Kit (PE) human
Miltenyi Biotec GmbH Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach, Germany Phone +49 2204 8306-0 Fax +49 2204 85197 macs@miltenyibiotec.de Miltenyi Biotec Inc. 12740 Earhart Avenue Auburn CA 95602,
More informationOverview 4/11/2013. Cell Kinetics in Adoptive Cell Therapy. April 11, 2013
Cell Kinetics in Adoptive Cell Therapy April 11, 2013 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationSupplementary Figure 1 CD4 + T cells from PKC-θ null mice are defective in NF-κB activation during T cell receptor signaling. CD4 + T cells were
Supplementary Figure 1 CD4 + T cells from PKC-θ null mice are defective in NF-κB activation during T cell receptor signaling. CD4 + T cells were isolated from wild type (PKC-θ- WT) or PKC-θ null (PKC-θ-KO)
More informationAdoptive Cellular Therapy SITC Primer October 2012
Adoptive Cellular Therapy SITC Primer October 2012 Cassian Yee MD Member Fred Hutchinson Cancer Research Center Program in Immunology Clinical Research Division Professor University of Washington Division
More informationSupplementary Information. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components
Supplementary Information Article Title Authors Supplementary Methods Supplementary Table S1 Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure S3 Potent inhibition of HIV-1 by TRIM5-cyclophilin
More informationApplication of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma
Excerpt from MACS&more Vol 8 1/2004 Application of μmacs Streptavidin MicroBeads for the analysis of HIV-1 directly from patient plasma L. Davis Lupo and Salvatore T. Butera HIV and Retrovirology Branch,
More informationData Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 60481
642 Cornerstone Court W, Ste B Tel: 1.858.829.382 Data Sheet IL-2-Luciferase Reporter (Luc) - Jurkat Cell Line Catalog # 6481 Description Human IL-2 reporter construct is stably integrated into the genome
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationNature Medicine: doi: /nm.2109
HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael
More informationSupplemental Experimental Procedures
Cell Stem Cell, Volume 2 Supplemental Data A Temporal Switch from Notch to Wnt Signaling in Muscle Stem Cells Is Necessary for Normal Adult Myogenesis Andrew S. Brack, Irina M. Conboy, Michael J. Conboy,
More informationCurrent Tumor Immunotherapy
Current Tumor Immunotherapy Part 1: On the preclinical and clinical efficacy of the current cancer vaccines. Part 2: The critical role of cancer vaccines in new integrative approaches. The State of the
More informationPeli1 negatively regulates T-cell activation and prevents autoimmunity
Peli1 negatively regulates T-cell activation and prevents autoimmunity Mikyoung Chang 1,*, Wei Jin 1,5,*, Jae-Hoon Chang 1, Yi-chuan Xiao 1, George Brittain 1, Jiayi Yu 1, Xiaofei Zhou 1, Yi-Hong Wang
More informationFor research or further manufacturing use only. Not for injection or diagnostic procedures.
PRIME-XV T cell Expansion XSFM PRIME-XV T Cell Expansion XSFM is a xeno-free, serum-free medium optimized for the activation and expansion of human T lymphocytes. This medium contains gentamicin and requires
More informationDissecting therapy-induced T-cell responses in melanoma
Dissecting therapy-induced T-cell responses in melanoma Tumor-infiltrating lymphocyte (TIL) therapy of melanoma TIL are grown from melanoma tumors Rapid Expansion Infusion of TIL + IL-2 Patient pretreated
More informationIn vitro human regulatory T cell expansion
- 1 - Human CD4 + CD25 + CD127 dim/- regulatory T cell Workflow isolation, in vitro expansion and analysis In vitro human regulatory T cell expansion Introduction Regulatory T (Treg) cells are a subpopulation
More information